Introduction
In the rational design of new radiopharmaceuticals for imaging of brain processes using PET (positron emission tomography) or SPECT (single photon emission computed tomography), candidate compounds are usually first selected on the basis of affinity and selectivity for the desired biochemical process (enzyme, receptor binding site, etc.). Modifications of the original structure are then considered, with two characteristics of primary importance: the ability of potential radiotracers to pass the bloodbrain-barrier, and exclusion of radiolabeled metabolites by the same membrane system. Radiotracers should show sufficient brain penetration to allow imaging within reasonable radiation dose limitations. Metabolites in the brain tissue, whether originating from brain metabolism or the product(s) of peripheral metabolism, may complicate quantitative mathematical modeling of the pharmacokinetics of the tracer; extensive metabolites in target tissue may negate the value of the radiotracer in uivo.
Extensive studies on the relationship between brain penetration and lipophilicity, including studies directly measuring brain uptake using a series of radiolabeled compounds (Raichle et al., 1975;  *All correspondence should be addressed to: Michael R. Kilboum, Ph.D., Division of Nuclear Medicine, 3480 Kresge III, University of Michigan, Ann Arbor, Ml 48109, U.S.A. Dischino et al., 1983) , or correlating drug efficacy and log P, have shown that there is apparently a "window" of optimum lipophilicity, centered near log P = 2 (Hansch et al., 1968; Glave et al., 1972; Biagi et al., 1980; Hansch and Clayton, 1973; Timmermans et al., 1977) . Radiotracers that fall below this window, and are highly polar, are poorly extracted by the brain unless an active transport system is available (such as with carbohydrates and amino acids). Radiotracers which are very lipophilic, and probably extensively and tightly bound to blood macromolecules, are also poorly extracted. Although there are certainly exceptions to this "optimum log P", it is remarkable how consistent the many disparate structure-activity studies have been, and the concept of altering the log P to maximize brain penetration (or, conversely, to prevent CNS activity: Hansch et al., 1987) is certainly worthwhile. It is thus often desirable to alter the lipophilicity of a radiotracer without changing the biological characteristics (affinity or specificity for intended physiological process). In some cases this has been very successful, as with the synthesis of radiolabeled butyrophenone neuroleptics: increasing the lipophilicity of spiperone by the attachment of a short alkyl or fluoroalkyl chain at the amide position gave derivatives with enhanced brain extraction and no loss of specificity or affinity for the dopamine D2 receptor, and thus improved imaging agents for PET (Welch et al., 1986) . Alterations in drug structures mtist also include considerations of metabolism; however, the design of radiotracers which will not suffer peripheral metabolism is more difficult, due to the efficiency of the hepatic metabolizing enzymes at handling xenobiotics. Although drug metabolism is a major area of research in pharmacology, it is not yet possible to always predict a priori the metabolic products of a given radiotracer structure.
The alteration of drug molecules by increasing or decreasing the length of alkyl chains is not a universal solution to increasing BBB permeability. Such changes may not be possible (lack of alkyl chains in the chemical structure); may yield derivatives with diminished specificity and affinity for the target system (receptor binding site, enzyme active site); or may produce undesirable metabolites. For example, we have previously prepared the dopamine reuptake inhibitor ['*F]GBR 13 119 (I-[(4-['*F]fluorophenyl)-(phenyl)methoxy)ethyl]-4-(3-phenylpropyl)-piperazine) as a potential imaging agent for PET (Kilbourn and Haka, 1988) . This molecule offers little in the way of alterations in structure: removing the ethoxy linkage yields a compound (]i8F]fluorocinnarizine; Kilbourn, unpublished) similar to flunnarizine and cinnarizine, which are calcium channel blockers with little in viva specificity (but possibly some affinity) for the dopamine uptake site. Altering the length of the 3-phenylpropyl moiety rapidly diminishes binding affinity ( phenylpropyl, IC,, = 1.9 nM; phenethyl, 6.7 nM; benzyl, 34 nM: Van der Zee et al., 1980) . Although a phenyl group cannot be "shortened" by one carbon, as cyclopentadiene is not equivalent to benzene, a reasonable option is the substitution of a thiophene ring. Thiophenes can be considered as bioisoteres of phenyl rings, and maintain the steric bulk, pi-electron cloud and planar structure of a phenyl ring. Thiophenes, however, are more polar (i.e. more hydrophilic) than phenyl groups (log P benzene = 2.15, thiophene = 1.81: Leo et al., 1971) , and thus are excellent candidates for a means to lower log P values of radiopharmaceuticals which are otherwise not amenable to significant alteration in structure. Thiophenes, due to the presence of a heteroatom and a more electron-rich aromatic ring, may also be metabolized by different routes or different rates (or both), as compared to the phenyl analogs. Although thiophenes have been evaluated as a portion of numerous new drugs (Press, 1986) less is known of the routes of metabolism of these compounds.
In this work, we have examined the substitution of a thiophene ring for one phenyl ring in the structure of [i'F]GBR 13 119, a dopamine reuptake inhibitor, to produce an entirely new compound we have termed thienyl-[i8F]GBR 13119. The effects of this substitution on the regional distribution in mouse brain have been examined. In preliminary experiments we have also investigated the synthesis of high specific activity, no carrier added "F-fluorinated thiophenes by nucleophilic aromatic substitution reactions.
Materials

Experimental
(4-Fluorophenyl)(2-thienyl)methanone was obtained from Lancaster Synthesis, Inc. S-Bromo-2-thiophene carboxaldehyde, 4-bromo-2-thiophenecarboxaldehyde, 5-nitro-2-thiophenecarboxaldehyde, N,N,N,N-tetraethylsulfamide, dimethylsulfoxide, lithium aluminum hydride (1 M in tetrahydrofuran, LAH), thionyl chloride, and toluene were obtained from Aldrich Chem Co. I-(2-Hydroxyethyl)-4-(3-phenylpropyl)piperazine was prepared by literature methods (Van der Zee et al., 1980). Thin layer chromatography was done using plastic-backed silica gel TLC plates (Eastman) and glass-backed C,, TLC plates (Whatman).
Production of ["F]Juoride
High specific activity ["Flfluoride ion was produced by the proton irradiation of I80 enriched water (95-99%, Isotec) held in an all-silver cyclotron target . TO the crude residue of chloride 3 was added 20 mg of N-(2-hydroxyethyl)-N-(3-phenylpropyl)-piperazine, one drop of toluene, and the mixture heated at 160°C for 25 min. After cooling, the dark residue was dissolved in 100 PL of methanol and added to 10 mL of water. The aqueous mixture was passed through a C-18 Sep-Pak and the solid phase washed with water. The products were then washed off with 2 mL of pentane, and the pentane solution passed through a silica gel Sep-Pak. The products are collected on the solid phase. The silica is washed with 40 mL of 50/50 pentane/CH,Cl,, and the product 4 eluted with 5 mL of 5% methanol/CH,Cl,.
The organic solvents were evaporated and the product formulated in 0.9% saline with a trace of hydrochlo- 
Animal studies
The regional brain distribution of thienyl-[18F]GBR 13 119 in CD-l mice was determined by methods previously described (Kilboum, 1988) . Animals (CD-l mice, 25-30 g, Charles River) were injected via the tail vein with 1.5-3.2mCi of radiotracer, then killed by decapitation at 60min. The brains were rapidly excised and dissected into the regions of interest (striatum, cerebellum, prefrontal cortex and remainder of brain tissue). A blood sample was also obtained. All samples were counted for '*F in an automatic y counter, then weighed. Data were calculated as "/ID/g for individual mice.
Results and Discussion
Modifications of radiopharmaceutical structures to maximize target organ uptake have most often involved changing the lengths of alkyl chains. In this work we have prepared a thiophene derivative of ["F]GBR 13119, for the first direct comparison of the in uiuo regional brain distribution of a thiophene-substituted drug with the phenyl substituted drug. Thiophene rings have previously formed parts of t8F labeled radiopharmaceuticals.
Thienylcyclohexylpiperidine, TCP, was labeled with 18F and examined for binding to the NMDA-receptor linked calcium channel (Kiesewetter er al., 1989) . A thienyl substituted amphetamine analog was prepared for possible application as a blood flow tracer (Goodman et al., 1989) . In both of these instances, however, the thiophene rings were part of the original pharmacologically active drug, and were not chosen as direct substitutions of the corresponding phenyl substituted drug, nor directly compared to the phenyl analog.
The synthesis of the thienyl analog of [t8F]GBR 13119 (4 , Fig 1: termed rhienyl-["FJGBR 13119) is straightforward and follows the synthetic sequence previously developed for [18F]GBR 13119 (Kilbourn and Haka, 1988; Haka et al., 1989) . The fluoro-substituted thienylphenylketone
(1) is commercially available and was used in this work. Nucleophilic exchange of t8F for 19F proceeds in expected yields of 20-30%, and the intermediate ketone can be reduced in situ with lithium aluminum hydride. Conversion to the benzylic chloride is via thionyl chloride and condensation with the alcohol, to form 4, done without added base. The product 4 is then isolated by solid-phase chromatographic columns as was [t8F]GBR 13119. The overall yield of thienyl-[18F]GBR 13119 (3-5%, EOS) is less than with the phenyl analog (lO-15% EOS) but this is directly attributable to the lower yield of the exchange reaction. By this synthetic route we have prepared modest amounts (360 PCi) of thienyl-[VIGBR 13119, with a specific activity of 1 Ci/mmol; higher specific activities and higher yields should be attainable by starting the synthesis with (4nitrophenyl)(2-thienyl)methanone, which can be prepared by Friedel-Crafts acylation of thiophene with 4-nitrobenzoyl chloride (Goncalves et al., 1952) . As was expected the thiophene compounds 1, 2, 3 and 4 all exhibit more polar nature on silica gel chromatography (as compared to the corresponding phenyl derivatives).
The regional brain distribution of thienyl-["F]GBR 13119 at 60 min in CD-l mice shows no differences when compared to that of [@F]GBR 13 119 determined in an identical protocol (Kilboum et al., submitted for publication). Selective uptake and accumulation in the striatum is observed, with excellent striatum/cerebellum ratios of more than 4 at 60 min (Table l) , which are maintained at 90 min (data not shown). Although the specific activity of the thienyl-[18F]GBR 13119 was quite low, the actual mass injected (16 rg/kg) did not apparently affect the in oivo biodistribution.
Thienyl-["F]GBR 13119 is an entirely new compound, which although from our studies of regional brain uptake appears to be a dopamine uptake inhibitor, it has not been fully characterized for affinity (IC,) or specificity (binding to other monoamine uptake systems, neurotransmitter receptors). The regional brain distribution would argue against a loss of specificity for the dopaminergic system; although it is not likely that thienyl for phenyl substitution might introduce dopamine receptor affinity, it has not been ruled out by this experimental protocol. Interestingly, a benzothiophene (N-[1-(2-benzo(b)thiophenyl)cyclohexyl]-piperidine, BTCP) has been recently described as a high affinity and selective inhibitor of dopamine uptake (Vignon et al., 1988) .
In this synthesis of thienyl-['*F]GBR 13119, we have substituted a thiophene ring for an unsubstituted phenyl ring. It would also be of value to prepare 'sF-fluorinated thiophene rings. Although numerous fluoro-substituted thiophene rings have been reported in the literature (Reinecke and Pedaja, 1986) , they have uniformly been prepared by electrophilic fluorination reactions, the best synthesis being via a thienyllithium reagent and perchloryl fluoride. Perchloryl
[r8F]fluoride has been prepared (Ehrenkaufer and MacGregor, 1983) and would be suitable for such syntheses, but this would result in carrier added ['sF]fluorothiophenes. We have examined the preparation of fluorothiophenes via nucleophilic aromatic substitution with ['*F]fluoride ion (Fig. 2) . Nucleophilic substitutions of thiophene rings are well known (Rienecke and Padaja, 1986; Scrowston, 1986; Norris, 1986) (TLC analysis) . The identical reaction with the corresponding 4-bromo thiophene (6) did not give any fluorinated products, and reaction with the S-nitro derivative (7) gave a low yield (6%) of 8 but predominantly decomposition of the starting material. The yields of the ['*F]F-for Br substitutions are certainly lower than that achieved for displacement of nitro groups or trimethylammonium groups attached to phenyl rings (Haka er al., 1989, and references therein), but are not unexpected for displacement of halogens. As in phenyl rings, there are orrho, meta and para relationships between thiophene ring substituents, with the 2,5-substitution pattern considered the equivalent of para in benzene rings. Thus, the greater reactivity of the 5-bromo (para) vs the 4-bromo (meta) thiophene-2-carboxaldehyde is not surprising. Nitro groups on thiophenes are extremely reactive and also very activating of the ring towards numerous reactions, and the decomposition of the starting material 7 may be due to base induced condensation reactions, ring opening reactions, or stable Meisenheimer complex formation, all of which have been described with nitrothiophenes. To the best of our knowledge, this nucleophilic fluorination ("F or 19F) of thiophenes is unprecedented in the chemical literature. As a wide number of substituted thiophenes are known, including numerous nitro and halogen substituted thiophenecarboxaldehydes, thiophenecarbonitriles and thiophenones (Scrowston 1986) , the incorporation of NCA [rsF#Iuoride into a thiophene ring may form a promising new alternative in radiopharmaceutical design.
Summary
We have evaluated two possible applications of thiophenes in radiopharmaceutical chemistry, the substitution of a thiophene for a phenyl ring, and the synthesis of a high specific activity r*F labeled thiophenes. Both of these approaches appear promising as new avenues for drug modification to enhance in uivo behavior. Further studies of thiophene compounds and thiophene-substituted drugs are in progress.
